Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

U.S. Stem Cell Inc (USRM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 13,925
  • Shares Outstanding, K 341,290
  • Annual Sales, $ 3,080 K
  • Annual Income, $ -2,070 K
  • 36-Month Beta 7.85
  • Price/Sales 2.83
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/21/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0350 +18.57%
on 02/02/18
0.0469 -11.51%
on 02/09/18
+0.0027 (+6.96%)
since 01/23/18
3-Month
0.0243 +70.78%
on 12/28/17
0.0560 -25.89%
on 11/28/17
+0.0120 (+40.68%)
since 11/22/17
52-Week
0.0096 +332.29%
on 02/24/17
0.1793 -76.85%
on 03/28/17
+0.0318 (+327.84%)
since 02/23/17

Most Recent Stories

More News
USRM Posts Live Webinar with World Renowned Biohacker

SUNRISE, Fla. , Feb. 20, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0415 (+1.72%)
USRM CSO to Host Live Stem Cell Info Webinar with World Renowned Biohacker

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0415 (+1.72%)
USRM Successfully Launches Stem Cell Webinar Series

Dr. Kristin Comella, Chief Science Officer of U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0415 (+1.72%)
USRM Successfully Launches Stem Cell Webinar Series

SUNRISE, Fla. , Feb. 12, 2018 /PRNewswire/ -- Dr. Kristin Comella , Chief Science Officer of U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem...

USRM : 0.0415 (+1.72%)
USRM Seeing Explosive Increase in Demand for Stem Cell Therapy

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive...

USRM : 0.0415 (+1.72%)
USRM Seeing Explosive Increase in Demand for Stem Cell Therapy

SUNRISE, Fla. , Feb. 6, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0415 (+1.72%)
USRM Chief Science Officer Featured in Powerful Stem Cell Docuseries

SUNRISE, Fla. , Jan. 24, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0415 (+1.72%)
USRM Reaches Key Sales Milestone of Proprietary Adipocell(TM) Product

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has reached a key milestone...

USRM : 0.0415 (+1.72%)
USRM Stem Cell Treatment Shows Promise in Enhancing Erectile Function

SUNRISE, Fla. , Jan. 8, 2018 /PRNewswire/ --  U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine...

USRM : 0.0415 (+1.72%)
USRM Stem Cell Treatment Shows Promise in Enhancing Erectile Function

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert...

USRM : 0.0415 (+1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Key Turning Points

2nd Resistance Point 0.0433
1st Resistance Point 0.0424
Last Price 0.0415
1st Support Level 0.0398
2nd Support Level 0.0381

See More

52-Week High 0.1793
Fibonacci 61.8% 0.1145
Fibonacci 50% 0.0944
Fibonacci 38.2% 0.0744
Last Price 0.0415
52-Week Low 0.0096

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.